These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27745574)

  • 21. Use of Lactulose in Hepatic Encephalopathy: Is It Time to Shift Targets?
    Sharma S; Chauhan A
    Clin Gastroenterol Hepatol; 2022 May; 20(5):e1220-e1221. PubMed ID: 34058412
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
    Huang E; Esrailian E; Spiegel BM
    Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Intestine specific broad spectrum antibiotic. Rifaximin: therapy option in hepatic encephalopathy].
    MMW Fortschr Med; 2014 Feb; 156(3):64-5. PubMed ID: 24938070
    [No Abstract]   [Full Text] [Related]  

  • 25. Lactulose and combination therapy of hepatic encephalopathy: the role of the intestinal microflora.
    Weber FL
    Dig Dis; 1996; 14 Suppl 1():53-63. PubMed ID: 8872452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
    Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J
    Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy.
    Horsmans Y; Solbreux PM; Daenens C; Desager JP; Geubel AP
    Aliment Pharmacol Ther; 1997 Feb; 11(1):165-70. PubMed ID: 9042989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of gut bacteria in the therapy of hepatic encephalopathy with lactulose and antibiotics.
    Dasarathy S
    Indian J Gastroenterol; 2003 Dec; 22 Suppl 2():S50-3. PubMed ID: 15025256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving treatments for hepatic encephalopathy.
    Gastroenterol Nurs; 2012; 35(4):291-2. PubMed ID: 22847290
    [No Abstract]   [Full Text] [Related]  

  • 30. [Hepatic encephalopathy -- preventative effects of lactulose].
    Z Gastroenterol; 2013 Aug; 51(8):708. PubMed ID: 24298621
    [No Abstract]   [Full Text] [Related]  

  • 31. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy?
    Butt NI; Butt UI; Kakar AATK; Malik T; Siddiqui AM
    J Coll Physicians Surg Pak; 2018 Feb; 28(2):115-117. PubMed ID: 29394969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Long-term efficacy of lactulose in patients with subclinical hepatic encephalopathy].
    Nie YQ; Zeng Z; Li YY; Sha WH; Ping L; Dai SJ
    Zhonghua Nei Ke Za Zhi; 2003 Apr; 42(4):261-3. PubMed ID: 12887812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can we ignore minimal hepatic encephalopathy any longer?
    Qadri AM; Ogunwale BO; Mullen KD
    Hepatology; 2007 Mar; 45(3):547-8. PubMed ID: 17326151
    [No Abstract]   [Full Text] [Related]  

  • 34. Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What?
    Henderson PK; Herrera JL
    Clin Liver Dis; 2015 Aug; 19(3):487-95. PubMed ID: 26195203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal treatment of hepatic encephalopathy.
    Waghray A; Waghray N; Kanna S; Mullen K
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].
    Abdo-Francis JM; Pérez-Hernández JL; Hinojosa-Ruiz A; Hernández-Vásquez JR
    Rev Gastroenterol Mex; 2010; 75(2):135-41. PubMed ID: 20615780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding.
    Aires FT; Ramos PT; Bernardo WM
    Rev Assoc Med Bras (1992); 2016; 62(3):243-7. PubMed ID: 27310548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo lactose and lactulose effects on colonic fermentation and portal-systemic encephalopathy parameters.
    Uribe-Esquivel M; Moran S; Poo JL; Muñoz RM
    Scand J Gastroenterol Suppl; 1997; 222():49-52. PubMed ID: 9145447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides.
    Morgan MY
    Metab Brain Dis; 2016 Dec; 31(6):1361-1364. PubMed ID: 27638474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic Management of Hepatic Encephalopathy.
    Khalessi A; Pyrsopoulos NT
    Clin Liver Dis; 2024 May; 28(2):287-296. PubMed ID: 38548440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.